drugset / Trial / NCT06581380

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

NCT06581380

Phase 3 Not yet recruiting 394 enrolled JenKem Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).

Timeline

Start
2024-09-16
Primary completion
2027-11-16
Completion
2028-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject JK-1201I Unknown 180 mg/m2 Intravenous
Comparator Topotecan Small molecule